Skin Squamous Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma arising from the squamous cells of the epidermis. Skin squamous cell carcinoma is most commonly found on sun-exposed areas. The majority of the tumors are well-differentiated. 
Skin squamous cell carcinomas most frequently harbor alterations in TP53, NOTCH1, CDKN2A, KMT2D, and ROS1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, NOTCH1 Mutation, and KMT2D Mutation are the most common alterations in skin squamous cell carcinoma .
There are 51 clinical trials for skin squamous cell carcinoma, of which 47 are open and 4 are completed or closed. Of the trials that contain skin squamous cell carcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 23 are phase 1 (19 open), 8 are phase 1/phase 2 (8 open), 16 are phase 2 (16 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).
BRAF and EGFR are the most frequent gene inclusion criteria for skin squamous cell carcinoma clinical trials .
Cemiplimab, pembrolizumab, and cetuximab are the most common interventions in skin squamous cell carcinoma clinical trials.
Significant Genes in Skin Squamous Cell Carcinoma
BRAF is altered in 6.76% of skin squamous cell carcinoma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for skin squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.